Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025

ZEVRA THERAPEUTICS, INC.

CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.
Separation benefits: 12 months base salary, 40% annual bonus, COBRA, full equity vesting.
Company has initiated search for new CFO; Neil F. McFarlane thanked Clifton for his leadership.
Clifton played role in company's transition from development to commercial-stage rare disease firm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.